Polynucleotide (PN) Skin Boosters — Why Korean Clinics Are Moving Beyond Hyaluronic Acid

For the past decade, non-crosslinked hyaluronic acid (HA) injections have been the default skin booster in aesthetic clinics worldwide. Products like Restylane Skinboosters and their Korean counterparts built an entire treatment category around one idea: inject HA into the dermis to hydrate from within. It worked. Patients loved the immediate glow. Clinics loved the rebooking cycle.

But something has shifted in Korean clinics — the same market that pioneered many of today's injectable innovations. An increasing number of practitioners are moving beyond HA-only protocols toward polynucleotide (PN) injectables. The reason isn't that HA stopped working. It's that PN does something HA fundamentally cannot.

The Limitation That HA Can't Solve

HA skin boosters are superb at one thing: binding water. A single molecule of hyaluronic acid can hold up to 1,000 times its weight in water, which is why patients see immediate plumping and hydration after treatment. But HA doesn't stimulate the skin to repair itself. It doesn't trigger collagen production. It doesn't rebuild the extracellular matrix. Once the body metabolizes the HA — typically within 3 to 6 months — the hydration effect disappears entirely.

For patients in their 20s and 30s whose skin fundamentally functions well but just needs a hydration boost, HA is perfectly adequate. But for the growing patient population in their 40s, 50s, and beyond — where the underlying issue is cellular slowdown, collagen degradation, and barrier dysfunction — hydration alone is a temporary fix for a structural problem.

How PN Changes the Equation

Polynucleotides are long-chain DNA fragments extracted from fish, most commonly salmon or salmon trout. When injected intradermally, PN operates through two biological pathways that HA cannot access.

The first pathway is receptor-mediated regeneration. PN fragments bind to A2A purinergic adenosine receptors on fibroblasts — the cells responsible for producing collagen and maintaining the dermal matrix. This receptor activation triggers a cascade of growth factor secretion and collagen synthesis that continues for weeks after the injection.

The second pathway is nucleotide salvage. PN provides ready-made building blocks for DNA repair, allowing aging or damaged cells to proliferate more efficiently than they could through de novo synthesis alone. This is particularly relevant for skin that has accumulated UV damage or chronic inflammatory stress.

The combined effect is that PN doesn't just hydrate the skin — it activates the skin's own repair machinery. The result is measurable improvement in elasticity, dermal thickness, and barrier function that persists well beyond the product's physical presence in the tissue.

What Practitioners Should Know About Current PN Products

The Korean PN injectable market now offers several competing products, each with slightly different formulation approaches.

The most established name is Rejuran, manufactured by PharmaResearch Products using their proprietary DOT™ technology with wild salmon DNA. The Rejuran line includes multiple variants targeting different treatment zones — Healer for general facial rejuvenation, HB for enhanced hydration, S for superficial fine lines, and I for the periorbital area. The Rejuran skin booster has built a strong clinical track record over several years and remains the benchmark against which newer PN products are compared.

More recently, a new generation of PN injectables has emerged with specific formulation improvements. One notable example is the Vitaran PN skin booster by BR Pharm, which uses an ionized PN formulation with optimized osmolarity and pH levels closer to natural skin. A clinical study published in an SCIE-indexed journal demonstrated reduced injection pain compared to standard PN products — addressing one of the most common patient complaints with polynucleotide treatments. BR Pharm also differentiates through vertical integration, managing its own salmon trout farms in Korea for end-to-end raw material control.

Clinical Decision Framework: When PN, When HA, When Both

The question for practitioners isn't whether to abandon HA in favor of PN — it's how to use both technologies strategically within a treatment plan.

HA skin boosters remain the right choice for patients primarily seeking hydration, patients with no significant collagen loss or structural concerns, quick-result treatments where immediate visible improvement matters most, and younger patients with fundamentally healthy skin who want maintenance.

PN injectables are better suited for patients with visible signs of dermal aging including loss of elasticity and fine lines, post-procedure recovery protocols where tissue regeneration is the goal, patients with compromised skin barriers from chronic inflammation or environmental damage, and treatment plans focused on long-term skin quality improvement rather than temporary hydration.

The most sophisticated approach — and the one increasingly adopted in Korean clinics — is alternating the two technologies within a single patient's treatment plan. HA sessions provide the immediate hydration patients want to see, while PN sessions drive the underlying structural repair that sustains results between visits. This staggered approach maximizes both patient satisfaction and per-patient revenue.

The Broader Shift Toward Regenerative Aesthetics

The PN movement is part of a larger industry shift from "replacement" thinking to "regeneration" thinking. Rather than simply replacing what the body has lost (volume, hydration, pigmentation correction), regenerative approaches activate the body's own repair mechanisms to rebuild from within.

This shift has implications beyond product selection. It changes how practitioners communicate value to patients — from "we'll fill what's missing" to "we'll help your skin repair itself." For clinics positioning themselves at the premium end of the market, this regenerative narrative resonates strongly with patients who want treatments that feel more biological and less cosmetic.

Korean manufacturers have been at the forefront of this shift, which is why the most advanced PN, PDRN, and exosome products continue to emerge from Korean R&D pipelines. Practitioners who want to stay ahead of the curve would do well to watch what Korean clinics are adopting today — because it reliably predicts what global clinics will be offering in two to three years.

*About the author: FillersFairy is a B2B supplier specializing in Korean aesthetic products for clinics and medspas worldwide.*

Powered by Froala Editor